Last update 29 Aug 2025

Changzhou Hansoh Pharmaceutical Co., Ltd.

Subsidiary Company|2018|Jiangsu Sheng, China

Overview

Tags

Neoplasms
Immune System Diseases
Urogenital Diseases
Small molecule drug
Antibody drug conjugate (ADC)
Bispecific antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms16
Immune System Diseases4
Endocrinology and Metabolic Disease4
Nervous System Diseases3
Hemic and Lymphatic Diseases2
Infectious Diseases2
Top 5 Drug TypeCount
Antibody drug conjugate (ADC)8
Small molecule drug4
Monoclonal antibody3
Biological products2
Bispecific antibody2
Top 5 TargetCount
EGFR x c-Met2
TYK2(Tyrosine-protein kinase 2)1
CLL-1(C-Type lectin domain family 12 member A)1
B7-H4(V-set domain-containing T-cell activation inhibitor 1)1
ROR1(Inactive tyrosine-protein kinase transmembrane receptor ROR1)1

Related

21
Drugs associated with Changzhou Hansoh Pharmaceutical Co., Ltd.
Inebilizumab-cdon
Target
CD19
Mechanism
CD19 inhibitors [+1]
Active Org.
Amgen, Inc.Amgen, Inc. [+9]
Originator Org.
Duke UniversityDuke University
Active Indication
Immunoglobulin G4-Related Disease [+6]
Inactive Indication
Aggressive B-Cell Non-Hodgkin Lymphoma [+11]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date11 Jun 2020
PM-1080
Target
EGFR x c-Met
Mechanism
EGFR antagonists [+1]
Active Org.
Shanghai Hansoh Biomedical Co. Ltd.Shanghai Hansoh Biomedical Co. Ltd. [+2]
Originator Org.
Biotheus, Inc.Biotheus, Inc.
Active Indication
Advanced Lung Non-Small Cell Carcinoma [+8]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
Mocertatug Rezetecan
Target
B7-H4
Mechanism
B7-H4 inhibitors
Active Org.
Shanghai Hansoh Biomedical Co. Ltd.Shanghai Hansoh Biomedical Co. Ltd. [+4]
Originator Org.
Shanghai Hansoh Biomedical Co. Ltd.Shanghai Hansoh Biomedical Co. Ltd.
Active Indication
Platinum-Resistant Epithelial Ovarian Carcinoma [+13]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
19
Clinical Trials associated with Changzhou Hansoh Pharmaceutical Co., Ltd.
CTR20243336
/ RecruitingPhase 1
HS-20117联合治疗在晚期实体瘤癌患者中的安全性、耐受性、有效性、药代动力学和免疫原性的Ib期临床研究
[Translation] A Phase Ib clinical study of the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of HS-20117 combination therapy in patients with advanced solid tumor cancers
CTR20243738
/ Active, not recruitingPhase 1
标准餐对HS-10390药代动力学影响的研究
[Translation] Study on the effect of standard meal on the pharmacokinetics of HS-10390
CTR20242658
/ CompletedPhase 1
不同规格HS-10374片之间药代动力学行为比较
[Translation] Comparison of pharmacokinetic behaviors of HS-10374 tablets of different strengths
100 Clinical Results associated with Changzhou Hansoh Pharmaceutical Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Changzhou Hansoh Pharmaceutical Co., Ltd.
Login to view more data
100 Deals associated with Changzhou Hansoh Pharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Changzhou Hansoh Pharmaceutical Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
7
2
Preclinical
IND Application
1
7
Phase 1
Phase 2
1
2
Phase 3
NDA/BLA
1
1
Other
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free